Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream
Status:
Withdrawn
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This research is being done to study whether using of topical tretinoin can help prevent the
common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I)
medications such ascetuximab or erlotinib.
Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their
face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and
topical or oral antibiotics. However, there has not yet been a study looking at a way to
prevent this common side effect from occurring, and topical tretinoin may be useful in
reducing the rash.
Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the
treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing
rashes associated with EGFR-I's.